LipocineLPCN
13F holders, Q4 2024 (December 31)17holders −1
1new positions
2sold out
1famous investor
$4.88avg. 13F price*
At the end of Q4 2024, 17 institutions reported holding Lipocine Inc. (LPCN) in their 13F filings, down 1 from Q3 2024. 1 opened new positions and 2 sold out. The largest holders were Vanguard Group Inc. ($1.1M), BlackRock, Inc. ($436K) and Geode Capital Management, LLC ($280K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Lipocine Inc.
- CUSIP
- 53630X203
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $317 |
| Exits | 2 | $598 |
All 13F filers, Q3 2024 → Q4 2024: 6,219 shares bought and 64,072 shares sold, net −57,853 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| Vanguard Group Inc. | 0.00% | No change | 221,459 | $1.1M |
| BlackRock, Inc. | 0.00% | No change | 89,272 | $436K |
| Geode Capital Management, LLC | 0.00% | Add +6.0% | 57,464 | $280K |
| Renaissance Technologies | 0.00% | Reduce -10.7% | 36,032 | $176K |
| Susquehanna International Group, LLP | 0.00% | Reduce -0.0% | 25,005 | $122K |
| Dimensional Fund Advisors LP | 0.00% | Add +13.9% | 20,516 | $100K |
| State Street Corp. | 0.00% | No change | 18,626 | $91K |
| Northern Trust Corp. | 0.00% | No change | 13,160 | $64K |
| Morgan Stanley | 0.00% | No change | 2,634 | $13K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +37.5% | 1,466 | $7K |
| Caldwell Sutter Capital, Inc. | 0.00% | No change | 471 | $2K |
| Osaic Holdings, Inc. | 0.00% | No change | 227 | $1K |
| Group One Trading LLC | 0.00% | Reduce -53.4% | 197 | $961 |
| FMR LLC | 0.00% | New | 65 | $317 |
| Bank of America Corp. | 0.00% | Add +10.7% | 62 | $303 |
| JPMorgan Chase & Co. | 0.00% | No change | 12 | $59 |
| UBS Group AG | 0.00% | Reduce -100.0% | 3 | $15 |
"% of holder's portfolio" is LPCN's weight in each manager's 13F, not the share of Lipocine Inc. the manager owns.